Rheumatic Heart Disease

Rheumatic Heart Disease (RHD) is a serious, preventable cardiovascular condition resulting from permanent damage to heart valves caused by one or more episodes of acute rheumatic fever (ARF). ARF is an autoimmune inflammatory reaction triggered by an untreated or inadequately treated group A Streptococcus (GAS) pharyngitis ("strep throat"). RHD primarily affects the mitral and aortic valves, leading to valvular stenosis, regurgitation, or both, which can progress to heart failure, arrhythmias, and other life-threatening complications if left untreated.

RHD is an autoimmune sequela of pharyngeal infection with Group A Streptococcus (GAS) bacteria, specifically Streptococcus pyogenes. The disease is not caused by the bacteria directly infecting the heart, but rather by the body's immune response to bacterial antigens (molecular mimicry) cross-reacting with host tissues, particularly in the heart, joints, brain, and skin. Genetic susceptibility, environmental factors like poverty, overcrowding, and limited access to healthcare contribute significantly to its prevalence.

Following a GAS pharyngeal infection, susceptible individuals develop an autoimmune response where antibodies and T-cells generated against GAS M-protein cross-react with similar epitopes on host proteins in the heart (myosin, laminin), joints, and brain. This "molecular mimicry" leads to acute inflammation (ARF). Repeated episodes of ARF cause chronic inflammation and fibrosis of the heart valves, particularly the mitral valve, and less commonly the aortic, tricuspid, and pulmonary valves. This damage results in leaflet thickening, fusion of commissures, chordal shortening, and calcification, impairing valve function, leading to stenosis (narrowing), regurgitation (leakage), or both, causing increased cardiac workload and ultimately heart failure.

RHD is a disease of poverty and disproportionately affects low- and middle-income countries, particularly in sub-Saharan Africa, South Asia, and the Pacific. Globally, it affects over 33 million people, causing over 300,000 deaths annually. Incidence peaks in children and young adults (5-15 years) for ARF, with RHD typically manifesting years later. There is no significant gender predisposition for ARF, but females tend to have a higher prevalence of severe RHD.

• Untreated or recurrent Group A Streptococcus (GAS) pharyngeal infections
• Poverty and low socioeconomic status
• Overcrowding and poor housing conditions
• Limited access to healthcare and antibiotic treatment
• Genetic predisposition (certain HLA alleles)
• Indigenous populations in developed countries

A. Early Symptoms (often asymptomatic or subtle)

• Fatigue


• Shortness of breath on exertion


• Palpitations B. Common Symptoms (as valvular damage progresses)


• Dyspnea (shortness of breath), initially on exertion, progressing to rest


• Orthopnea (difficulty breathing when lying flat)


• Paroxysmal nocturnal dyspnea (PND)


• Chest pain or discomfort


• Palpitations


• Fatigue and weakness


• Swelling in ankles, feet, abdomen (edema)


• Cough C. Advanced Symptoms (indicating severe heart failure)


• Severe dyspnea at rest


• Anasarca (generalized swelling)


• Cyanosis


• Hepatomegaly (enlarged liver)


• Cachexia (wasting syndrome)


• Symptoms of pulmonary hypertension D. Emergency Symptoms


• Acute pulmonary edema (sudden, severe shortness of breath)


• Stroke-like symptoms (weakness, numbness, speech difficulties) due to emboli


• Sudden onset severe chest pain


• Syncope (fainting)


• Irregular heartbeat with rapid progression of symptoms

• Vital signs: Tachycardia, tachypnea, hypotension or hypertension, signs of heart failure (elevated JVP).
• Inspection: Peripheral edema, ascites, pallor, evidence of prior ARF (e.g., subcutaneous nodules, chorea are rare in chronic RHD).
• Palpation: Displaced apex beat (cardiomegaly), thrills over precordium, hepatomegaly.
• Auscultation: Characteristic heart murmurs reflecting valvular stenosis (e.g., diastolic rumble of mitral stenosis, systolic ejection murmur of aortic stenosis) or regurgitation (e.g., holosystolic murmur of mitral regurgitation, early diastolic murmur of aortic regurgitation). Gallop rhythm (S3 or S4) in heart failure. Pulmonary crackles.

A. Clinical Assessment
Detailed history of recurrent sore throats, previous ARF, and current cardiac symptoms. Physical examination for signs of heart failure and characteristic murmurs.
B. Laboratory Testing
To confirm prior GAS infection or ongoing inflammation.
C. Imaging Studies
Echocardiography is the cornerstone for diagnosis and severity assessment.
D. Functional Tests
ECG to detect arrhythmias, chamber enlargement. Exercise testing in select cases.
E. Biopsy Findings
Not typically used for routine diagnosis of RHD.
F. Genetic Testing
Not routinely performed for RHD diagnosis, research setting only.
G. Differential Diagnosis
Congenital heart disease, other causes of valvular heart disease (e.g., degenerative, infective endocarditis), myocarditis.

Anti-streptolysin O (ASO) Titre
Type: Blood Test
Purpose: Detects antibodies against streptolysin O, indicating recent GAS infection.
Expected Findings: Elevated titre in recent GAS infection.
Interpretation: High or rising titres support a recent GAS infection, a prerequisite for ARF/RHD.
Anti-DNAse B Titre
Type: Blood Test
Purpose: Detects antibodies against streptococcal deoxyribonuclease B, indicating recent GAS infection.
Expected Findings: Elevated titre.
Interpretation: More sensitive than ASO for skin infections, also elevated in pharyngeal infections.
C-Reactive Protein (CRP)
Type: Blood Test
Purpose: Marker of systemic inflammation.
Expected Findings: Elevated during acute inflammatory phases (e.g., ARF exacerbation, infective endocarditis).
Interpretation: Non-specific, but useful for monitoring inflammatory activity.
Erythrocyte Sedimentation Rate (ESR)
Type: Blood Test
Purpose: Marker of systemic inflammation.
Expected Findings: Elevated during acute inflammatory phases.
Interpretation: Non-specific, but useful for monitoring inflammatory activity.
Complete Blood Count (CBC)
Type: Blood Test
Purpose: Assess for anemia, infection.
Expected Findings: May show leukocytosis during acute inflammation; anemia in chronic disease.
Interpretation: Provides general health information.

Echocardiography (Transthoracic and Transesophageal)
Purpose: Gold standard for visualizing heart valves, chambers, and assessing cardiac function.
Typical Findings: Thickened, restricted, or calcified valve leaflets; fused commissures; shortened chordae tendineae; valvular regurgitation or stenosis; chamber enlargement; ventricular dysfunction; pulmonary hypertension.
Clinical Importance: Confirms RHD diagnosis, quantifies severity of valve lesions, guides management decisions (medical vs. surgical), monitors progression.
Chest X-ray (CXR)
Purpose: Assesses heart size, pulmonary vasculature, and signs of heart failure.
Typical Findings: Cardiomegaly (enlarged heart), pulmonary congestion, Kerley B lines (in pulmonary edema).
Clinical Importance: Supports diagnosis of heart failure and monitors its severity, not specific for RHD itself.
Electrocardiogram (ECG)
Purpose: Detects arrhythmias, chamber enlargement, and signs of myocardial ischemia.
Typical Findings: Atrial fibrillation (common in mitral stenosis), left atrial enlargement, left ventricular hypertrophy, signs of right ventricular strain in pulmonary hypertension.
Clinical Importance: Identifies associated electrical abnormalities and helps assess the impact of valvular disease on cardiac chambers.
Cardiac Magnetic Resonance Imaging (MRI)
Purpose: Provides detailed anatomical and functional assessment of the heart, particularly useful for complex cases or when echo is limited.
Typical Findings: Precise quantification of valvular regurgitation and stenosis, myocardial fibrosis, ventricular volumes and function.
Clinical Importance: Complementary to echocardiography, especially for detailed anatomical assessment and evaluation of myocardial tissue.

• Congenital Valvular Heart Disease: Distinguished by absence of preceding ARF and often different valve morphology.
• Degenerative Valvular Disease: Typically affects older patients, absence of ARF history, different pathological features.
• Infective Endocarditis: Acute onset of fever and murmurs, positive blood cultures, vegetations on echocardiography. RHD patients are at higher risk.
• Myocarditis: Inflammation of heart muscle, not primarily valvular.
• Other Cardiomyopathies: Different underlying causes of heart failure and chamber enlargement.

• Heart Failure: Most common and severe complication, leading to dyspnea, edema, and reduced quality of life.
• Arrhythmias: Atrial fibrillation is particularly common, increasing stroke risk.
• Stroke and Systemic Embolism: Due to clot formation in the heart chambers, especially with atrial fibrillation and severe mitral stenosis.
• Infective Endocarditis: Increased susceptibility to bacterial infection of damaged heart valves.
• Pulmonary Hypertension: Elevated pressure in pulmonary arteries due to left-sided heart failure.
• Peripartum Complications: Increased risk for pregnant women with RHD.
• Sudden Cardiac Death: Rare but possible, especially in severe cases.

A. Lifestyle Modifications
Regular exercise (as tolerated), healthy diet (low sodium), smoking cessation, alcohol moderation, weight management.
B. Preventive Measures
Primary prevention: Prompt and adequate antibiotic treatment (penicillin) for GAS pharyngitis.
Secondary prevention: Long-term antibiotic prophylaxis (typically intramuscular benzathine penicillin G every 3-4 weeks) to prevent recurrent ARF episodes and progression of RHD.
C. Medical Treatment

• Diuretics (e.g., Furosemide, Spironolactone) Mechanism: Reduce fluid overload, alleviate symptoms of heart failure. Examples: Furosemide, hydrochlorothiazide.


• ACE Inhibitors/ARBs (e.g., Lisinopril, Valsartan) Mechanism: Reduce afterload, improve cardiac output, prevent ventricular remodeling. Examples: Lisinopril, enalapril, valsartan.


• Beta-blockers (e.g., Metoprolol, Carvedilol) Mechanism: Reduce heart rate, improve diastolic filling, decrease myocardial oxygen demand. Examples: Metoprolol, carvedilol.


• Anticoagulants (e.g., Warfarin, DOACs) Mechanism: Prevent thromboembolism, especially in atrial fibrillation or mechanical valve replacement. Examples: Warfarin, dabigatran.


• Digoxin Mechanism: Improves contractility, slows ventricular rate in atrial fibrillation. Examples: Digoxin.

• Valve Repair: Preferred for selected cases of mitral regurgitation (e.g., commissurotomy, annuloplasty).


• Valve Replacement: Indicated for severe, symptomatic valvular stenosis or regurgitation not amenable to repair. Can be mechanical or bioprosthetic valves.

• Balloon Valvuloplasty: Percutaneous procedure to widen stenotic mitral or pulmonary valves, less commonly aortic valve.

The prognosis for RHD is highly variable, depending on the severity of valve damage, recurrence of ARF, access to treatment, and compliance with secondary prophylaxis. With timely diagnosis, effective secondary prophylaxis, and appropriate medical/surgical management, the progression of the disease can be slowed, and complications reduced. However, without intervention, it often leads to chronic heart failure and premature death, especially in young adults. Recurrent ARF episodes worsen the prognosis significantly.

Primary prevention: Early and complete treatment of Group A Streptococcus pharyngitis with antibiotics (e.g., penicillin) to prevent the initial episode of ARF.
Secondary prevention: Continuous antibiotic prophylaxis (e.g., benzathine penicillin G every 3-4 weeks) in individuals who have had ARF or have diagnosed RHD, to prevent recurrent ARF episodes and progression of valvular damage.
Screening: Echocardiographic screening programs in high-risk populations to identify early RHD.

The following homeopathic remedies have been historically indicated for symptoms associated with Rheumatic Heart Disease. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Advanced Cardiovascular & Lipid Analyzer

Evaluates Hypertension Stage (AHA), Mean Arterial Pressure (MAP), Pulse Pressure, Vascular Age, and 10-Year ASCVD Heart Attack Risk — all from a single clinical profile.